NEW YORK, Feb. 1, 2017 /PRNewswire/ -- Connecting Patients and Caregivers
For self-administration, adherence with drug therapy and disease management protocols has become a primary concern within the healthcare and pharmaceutical industries. For chronic conditions adherence has a direct effect on the patient's quality-of-life. Wirelessly enabled devices – drug injection devices that are designed to address the patient adherence issue by reminding and recording data about patient dosing activity and making it available to HCPs – are gaining interest among industry and managed care participants. Efforts to enhance adherence have a non-negligible effect on drug formulations and delivery decisions, and are a significant factor in the prescribing decisions of most physicians. The connected device ecosystem includes OEM device suppliers, drug developers, human factors consultants and aftermarket third-party devices.
Market-driven Product Strategies
A longer life span is expected to translate to a growing number of patients diagnosed with chronic conditions. To counteract the financial and medical infrastructure implications of this trend, pressure from the public sector and managed care organizations will place a premium on therapeutic self-administration, an expectation that is creating an increased interest in routes of administration that are patient-friendly and cost-effective. Pharma company decision makers have come to the realization that for many products, success no longer only depends on the medication itself but also on achieving a consumercompatible form of packaging and application.
'Much of the activity surrounding connected drug injection devices is focused on chronic diseases – conditions where the ability of caregivers to access data on patient self-administration activities, patient reported outcomes, and feedback on the user experience can yield significant benefits in patient Quality of Life.'
What You Will Learn
• What drug injection devices incorporate wireless connectivity technology, how do they work and what new capabilities do they offer to patients and their HCPs?
• What benefits do wirelessly enabled drug injectors provide to patients in the area of improved adherence? Patient reported outcomes? HCP/patient communication?
• What therapeutic areas are the current focus of wirelessly enabled devices?
• Who are the companies behind the growth of wirelessly enabled injection devices? What are their development activities and corporate alliances and affiliations
• What is the importance of pharma-device alliances and design partnerships on wirelessly enabled drug injection device commercialization and market access?
• What does the current market for wirelessly enabled drug injection devices look like? What will it look like in 2022?
• What are the key market drivers for the growth of wirelessly enabled injection devices?
Who Should Read this Report
• Drug Developers
• Device Suppliers
• Clinical Trial Mgmt
• Pharma Managers
• Biotech Managers
• Drug Marketers
• Industry Strategists
• Financial Analysts
• Management Consultants
• Clinical Managers
• Drug Distributors
• Pharma Regulators
• FDA Consultants
• Managed Care Managers
Read the full report: http://www.reportlinker.com/p04665928-summary/view-report.html
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
Contact Clare: email@example.com
Intl: +1 339-368-6001
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/wirelessly-enabled-injection-devices-to-2022-300400764.html